Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 05 Oct, 13:52 UTC

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

science

Sources

• T2Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine dataBioPharma Dive / Healthcare Dive / MedTech Dive05 Oct, 13:52